Clinical trial update: Neuroprotection against acute ischaemic stroke

Current Opinion in Neurology

Volumn 12, Issue 1, 1999, Pages 73-79

  Devuyst, Gérald ^a   Bogousslavsky, Julien ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CALPAIN; CITICOLINE; CLOMETHIAZOLE; DIZOCILPINE MALEATE; EBSELEN; ELIPRODIL; FOSPHENYTOIN SODIUM; GAVESTINEL; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; MAGNESIUM; MONOCLONAL ANTIBODY; MONOSIALOGANGLIOSIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALMEFENE; NIMODIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; PIRACETAM; PROPENTOFYLLINE; SEROTONIN ANTAGONIST; TIRILAZAD; UNCLASSIFIED DRUG;

CEREBROVASCULAR ACCIDENT; FEVER; HUMAN; INFECTION; LONG QT SYNDROME; NEPHROTOXICITY; NEUROPROTECTION; QT INTERVAL; REVIEW;

ACUTE DISEASE; BRAIN ISCHEMIA; CLINICAL TRIALS; HUMANS; HYPOTHERMIA; NEUROPROTECTIVE AGENTS;

EID: 0033012708     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199902000-00012     Document Type: Review

References (41)

1. 1 Silver B, Weber J, Fisher M. Review; medical therapy for ischemic stroke. Clin Neuropharmacol 1996; 19:101-128.
2. 2 Mohr JP, Orgogozo JM, Harrison MJG, Hennerici M, Wahlgren NG, Gelmers JH, et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4:197-203.
3. 3 Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T, for the INWEST study group. Intravenous Nimedipine West European Stroke Trial of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994; 4:204-210.
4. 4 Davis SM, Albers GW, Diener HC, Lees KR, Norris J. Termination of acute stroke studies involving selfotel treatment [letter]. ASSIST Steering Committee. Lancet 1997; 349:32.
5. 5 Edwards K and the CNS 1102-008 Study Group. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: results of phase 2 trial. Neurology 1996; 46(Suppl 1):A424.
6. 6 Albers GW, Atkinson RP, Kelley RE, Roseabaum MD on behalf of the Dextrorphan Study Group. Safety. tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995; 26:254-258.
7. 7 Albers GW, Atkinson RP, Kelley RE for The Dextromethorphan Study Group and Hoffmann-La Roche. Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist Ro-01-6794/706 in patients with acute ischemic stroke. Ann NY Acad Sci 1995; 765:249-261.
8. 8 Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997; 49(Suppl 4):S66-S69.
9. 9 Kurumaji A, Ikeda M, Dewar D, McCormack AG, McCulloch J. Effects of chronic administration of MK-801 upon local cerebral glucose utilisation and ligand binding to the NMDA receptor complex. Brain Res 1991; 563:57-65.
10. 10 Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Storts RW, et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 1993; 123:204-215.
11. 11 Lees KR. Does neuroprotection improve stroke outcome? Lancet 1998; 351:1447-1448.
12. 12 Lees KR, Lavelle JF, Hobbiger SF, GAIN European Study Group. Safety and tolerability of GV150526 in acute stroke (GLYB2002). Cerebrovasc Dis 1998; 8(Suppl 4):20.
13. 13 Grotta J for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke 1997; 28:2338-2346.
14. 14 Önal MZ, Fisher M. Acute Ischemic Stroke Therapy. A clinical overview. Eur Neurol 1997; 38:141-154.
15. 15 Diener HC, for the European and Australian Lubeluzole Ischaemic Stroke Study Group. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. Cerebrovasc Dis 1998; 8:172-181.
16. 16 The RANTTAS Investigators, a randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996; 27:1453-1458.
17. 17 Haley EC on behalf of the RANTTAS II Investigators. High-Dose Tirilazad for acute stroke (RANTTAS II). Stroke 1998; 29:1256-1257.
18. 18 Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H for the Ebselen Study Group. Ebselen in acute ischemic stroke. A placebo-controlled, double-blind clinical trial. Stroke 1998; 29:12-17.
19. 19 Wahlgren NG and the Clomethiazole Acute Stroke Study Collaborative Group. The Clomethiazole Acute Stroke Study (CLASS) [abstract]. Cerebrovasc Dis 1997; 7(Suppl 4):19.
20. 20 Walghren NG, Clomethiazole Acute Stroke Study Collaborative Group. The Clomethiazole Acute Stroke Study (CLASS): results in 94 haemorrhagic stroke patients. Cerebrovasc Dis 1998; 8(Suppl 4):20.
21. 21 Fisher M, Bogousslavsky J. Further evolution toward effective therapy for acute ischemic stroke. Special communication. JAMA 1998; 279: 1298-1303. This critical and timely review of all stroke therapies includes neuroprotection and further perspectives.
22. 22 The Enlimomab Acute Stroke Trial Investigators. The Enlimomab Acute Stroke Trial: final results [abstract]. Neurology 1997; 48:A270.
23. 23 De Deyn PP, De Reuck J, Deberdt W, Vlietinck R, Orgogozo JM for Members of the Piracetam in Acute Stroke Study (PASS) Group. Treatment of acute ischemic stroke with Piracetam. Stroke 1997; 28:2347-2352.
24. 24 Weiss GB. Mini review: metabolism and actions of citicoline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995; 56:637-660.
25. 25 Clark WM, Warach SJ, Pettigrew LC, et al. A randomized dose-response trial of citicoline in acute ischemic stroke. Neurology 1997; 49:671-678.
26. 26 Goldszmidt A, Wityk RJ. Recent advances in stroke therapy. Curr Opin Neurol 1998; 11:57-64. This is a very complete overview of all stroke treatments available to date.
27. 27 Wahlgren NG. Cytoprotective therapy for acute ischemic stroke. In: Fisher M (editor). Stroke therapy. Boston: Butterworth-Heinemann; 1995. pp. 315-350.
28. 28 Muir KW, Lees KR. Images: intravenous magnesium efficacy in stroke trial [abstract]. Cerebrovasc Dis 1996; 6:75-P383.
29. 29 Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995; 26:1183-1188.
30. 30 Teal P on behalf of the BRAIN Study Group, BRAINS, a Phase II study of the neuroprotectant BAY 3702 in patients with ischemic stroke. Cerebrovasc Dis 1998; B(Suppl 4):20.
31. 31 Silver B, Weber J, Fisher M. Trends in protecting ischemic brain. In: Bogousslavksy J (editor): Acute stroke treatment. UK: Martin Dunitz; 1997. pp. 149-162.
32. 32 Ginsberg MD, Busto R. Combating hyperthermia in acute stroke. A significant clinical concern. Stroke 1998; 29:529-534.
33. 33 Schwab S, Spranger M, Aschoff A, Steiner T, Hacke W. Brain temperature monitoring and modulation in patients with severe MCA infarction. Neurology 1997; 48:762-767.
34. 34 Hindfelt B. The prognostic significance of subfebrility and fever in ischemic cerebral infarction. Acta Neurol Scand 1976; 53:72-79.
35. 35 Castillo J, Martinez F, Leira R, Prieto JM, Lema M, Noya M. Mortality and morbidity of acute cerebral infarction related to temperature and basal analytic parameters. Cerebrovasc Dis 1994; 4:56-71.
36. 36 Azzimondi G, Bassein L, Nonino F, Fiorani L, Vignatelli L, Re G, D'Alessandro R. Fever in acute stroke worsens prognosis: a prospective study. Stroke 1995; 26:2040-2043.
37. 37 Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, Olsen TS. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality and outcome. Lancet 1996; 347:422-425.
38. 38 Caplan LR. Stroke treatment. Promising but still struggling [editorial]. JAMA 1998; 279:1304-1306.
39. 39 Strauss WE, Thies WH, Robertson RM, Adams H. Fighting heart disease and stroke. Recommendations of the AHA stroke positioning task force. Stroke 1998; 29:1272-1273.
40. 40 Dyker AG, Lees KR. Duration of neuroprotective treatment for ischemic stroke. Stroke 1998; 29:535-542. This paper explains the limits of action of the neuroprotective drugs, according to their pharmacokinetic properties, their mode of action and the time window.
41. 41 Sacco RL, Fisher M. Prophylactic neuroprotection for pretreatment of brain infarction. In: Bogousslavksy J (editor): Acute stroke treatment. UK: Martin Dunitz; 1997. pp. 271-284.